WO2019035605A3 - 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 - Google Patents

리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 Download PDF

Info

Publication number
WO2019035605A3
WO2019035605A3 PCT/KR2018/009173 KR2018009173W WO2019035605A3 WO 2019035605 A3 WO2019035605 A3 WO 2019035605A3 KR 2018009173 W KR2018009173 W KR 2018009173W WO 2019035605 A3 WO2019035605 A3 WO 2019035605A3
Authority
WO
WIPO (PCT)
Prior art keywords
lipopeptide
liposome
antigen
present
effective ingredient
Prior art date
Application number
PCT/KR2018/009173
Other languages
English (en)
French (fr)
Other versions
WO2019035605A9 (ko
WO2019035605A2 (ko
Inventor
염정선
안병철
조현진
백승희
정은정
정수경
신나리
Original Assignee
주식회사 차백신연구소
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180005418A external-priority patent/KR102098097B1/ko
Application filed by 주식회사 차백신연구소 filed Critical 주식회사 차백신연구소
Priority to CN201880052947.3A priority Critical patent/CN110996999A/zh
Priority to EP18846714.6A priority patent/EP3669891A4/en
Priority to US16/639,302 priority patent/US11612650B2/en
Priority to JP2020531405A priority patent/JP7080513B2/ja
Priority to CA3072895A priority patent/CA3072895C/en
Priority to AU2018317120A priority patent/AU2018317120B2/en
Publication of WO2019035605A2 publication Critical patent/WO2019035605A2/ko
Publication of WO2019035605A3 publication Critical patent/WO2019035605A3/ko
Publication of WO2019035605A9 publication Critical patent/WO2019035605A9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 리포좀 및 리포펩티드를 포함하는 재조합 대상포진 백신 및 이의 제조방법에 관한 것이다. 구체적으로, 본 발명의 리포좀 및 다양한 종류의 리포펩티드를 포함하는 복합 아쥬반트인 Lipo-Pam과 바리셀라-조스터 바이러스 gE 항원 또는 일본뇌염 바이러스 gE 항원 또는 계절형 불활화 독감 바이러스(seasonal inactivated influenza virus) 항원을 이용하여 제조한 백신 조성물이 체액성 면역반응 뿐만 아니라 세포성 면역반응도 높게 유도함으로써, 본 발명의 조성물은 상업적으로 유용하게 사용될 수 있다.
PCT/KR2018/009173 2017-08-16 2018-08-10 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 WO2019035605A2 (ko)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CN201880052947.3A CN110996999A (zh) 2017-08-16 2018-08-10 包含插入有脂肽的脂质体作为有效成分的疫苗佐剂及其用途
EP18846714.6A EP3669891A4 (en) 2017-08-16 2018-08-10 VACCINE ADJUVANS WITH LIPOPEPTIDE-INSERTED LIPOSOME AS THE ACTIVE SUBSTANCE AND USE OF IT
US16/639,302 US11612650B2 (en) 2017-08-16 2018-08-10 Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof
JP2020531405A JP7080513B2 (ja) 2017-08-16 2018-08-10 有効成分としてリポペプチド挿入リポソームを含むワクチンアジュバントおよびその使用
CA3072895A CA3072895C (en) 2017-08-16 2018-08-10 Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof
AU2018317120A AU2018317120B2 (en) 2017-08-16 2018-08-10 Vaccine adjuvant comprising lipopeptide-inserted liposome as effective ingredient and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0103788 2017-08-16
KR20170103788 2017-08-16
KR10-2018-0005418 2018-01-16
KR1020180005418A KR102098097B1 (ko) 2017-08-16 2018-01-16 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도

Publications (3)

Publication Number Publication Date
WO2019035605A2 WO2019035605A2 (ko) 2019-02-21
WO2019035605A3 true WO2019035605A3 (ko) 2019-04-25
WO2019035605A9 WO2019035605A9 (ko) 2019-06-06

Family

ID=65362200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/009173 WO2019035605A2 (ko) 2017-08-16 2018-08-10 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도

Country Status (1)

Country Link
WO (1) WO2019035605A2 (ko)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150064240A1 (en) * 2011-02-24 2015-03-05 Oncothyreon Inc. MUC1 Based Glycolipopeptide Vaccine with Adjuvant
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
KR20160007640A (ko) * 2013-05-14 2016-01-20 메르크 파텐트 게엠베하 Muc-1 리포펩티드를 이용한 백신접종에 의한 폐암의 치료 방법
US20160256542A1 (en) * 2002-04-04 2016-09-08 Carlos Alberto Guzman Use of a Lipopeptide or Lipoprotein as an Adjuvant in Therapeutic or Prophylactic Vaccinations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013009723A (es) 2011-02-24 2013-09-16 Mogam Biotech Res Inst Cepas del virus de varicela-zoster novedosas, y vacunas del virus del herpes zoster y varicela usando los mismos.
KR101723605B1 (ko) 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160256542A1 (en) * 2002-04-04 2016-09-08 Carlos Alberto Guzman Use of a Lipopeptide or Lipoprotein as an Adjuvant in Therapeutic or Prophylactic Vaccinations
US20150064240A1 (en) * 2011-02-24 2015-03-05 Oncothyreon Inc. MUC1 Based Glycolipopeptide Vaccine with Adjuvant
KR101501583B1 (ko) * 2013-03-29 2015-03-12 주식회사 차백신연구소 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물
KR20160007640A (ko) * 2013-05-14 2016-01-20 메르크 파텐트 게엠베하 Muc-1 리포펩티드를 이용한 백신접종에 의한 폐암의 치료 방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BAL, SUZANNE M. ET AL.: "Co-encapsulation of Antigen and Toll-like Receptor Ligand in Cationic Liposomes Affects the Quality of the Immune Response in Mice after Intradermal Vaccination", VACCINE, vol. 29, no. 5, 2011, pages 1045 - 1052, XP055165405, DOI: doi:10.1016/j.vaccine.2010.11.061 *

Also Published As

Publication number Publication date
WO2019035605A9 (ko) 2019-06-06
WO2019035605A2 (ko) 2019-02-21

Similar Documents

Publication Publication Date Title
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
MX2022009989A (es) Composiciones inmunogenicas y vacunas para covid-19 vectorizadas por sarampion.
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
NZ597182A (en) Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
WO2017096341A3 (en) Adenovirus-vectored multivalent vaccine
WO2015195218A8 (en) Polyvalent influenza virus-like particles (vlps) and use as vaccines
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2015142671A3 (en) Influenza virus vectors and uses therefor
WO2016007576A3 (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
TW200806316A (en) Yeast-based vaccine for inducing an immune response
PH12019550106A1 (en) Herpes zoster vaccine composition
WO2015103167A3 (en) Single vial vaccine formulations
AR080111A1 (es) Metodos y composiciones de inmunizacion
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
WO2017142843A8 (en) Novel antigen for use in malaria vaccine
PH12019501569A1 (en) Universal influenza vaccine compositions
BR112014023414A8 (pt) Vacina de herpesvirus-1 equino recombinante contendo uma glicoproteína c mutante e seus usos
MX2020012469A (es) Variante de antigeno de virus de varicela zoster y uso de la misma.
AU2018388102A1 (en) Cross-immunizing antigen vaccine and method for preparation thereof
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
NZ739260A (en) Inactivated canine influenza vaccines and methods of making and uses thereof
MX2020002810A (es) Composicion inmunogenica de citomegalovirus humano.
MX363149B (es) Vacunas de nucleoproteina de la influenza.
AU2015364253B2 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for H1N1 influenza

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846714

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3072895

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020531405

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018317120

Country of ref document: AU

Date of ref document: 20180810

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018846714

Country of ref document: EP

Effective date: 20200316